Long-Term Effectiveness and Reasons for Discontinuation of Dupilumab in Patients With Atopic Dermatitis
JAMA Dermatology · 01.10.2024 · 160 (10) · 1044
DOI: 10.1001/jamadermatol.2024.2517 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JAMA Dermatology, erschienen am 01.10.2024. Verfasst von Celeste M Boesjes und 23 weiteren Autor:innen. Beteiligte Einrichtung: National Expertise Center for Atopic Dermatitis, Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, the Netherlan…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Dermatitis, Atopic, Withholding Treatment. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Limited data are available on the long-term effectiveness and safety of dupilumab for atopic dermatitis (AD) in daily practice.
Objective
To evaluate clinical effectiveness and reasons for discontinuation of dupilumab treatment in children, adults, and older adults with AD with up to 5 years of treatment in daily practice. Design, Setting, and Participants This prospective multicenter cohort study was conducted using the BioDay registry (4 academic and 10 nonacademic hospitals in the Netherlands) to identify patients with AD of all ages who were treated with dupilumab between October 2017 and December 2022. Main Outcomes and Measures Clinical effectiveness was evaluated by the Eczema Area and Severity Index (EASI), Investigator Global Assessment (IGA), and numeric rating scale (NRS) for pruritus, stratified by children (<18 years), adults (18-64 years), and older adults (≥65 years). In addition, time to response, treatment responders, EASI subscores, second treatment episodes, and thymus- and activation-related chemokine and eosinophil levels were assessed. For patients who discontinued dupilumab, the reason for discontinuation was evaluated.
Results
In total, 1286 patients with AD (median [IQR] age, 38 [26-54] years; 726 [56.6%] male) were treated with dupilumab, including 130 children, 1025 adults, and 131 older adults. The median (IQR) follow-up time was 87.5 (32.0-157.0) weeks. Most patients maintained controlled AD, with EASI of 7 or lower and NRS for pruritus of 4 or lower varying between 78.6% and 92.3% and 72.2% and 88.2% for up to 5 years of treatment, respectively, while up to 70.5% of all patients prolonged the dosing interval to mostly 300 mg every 3 or 4 weeks. Mean EASI and NRS for pruritus were 2.7 (95% CI, 1.2-4.2) and 3.5 (95% CI, 2.7-4.3), respectively, after 5 years of treatment. Statistically significant differences between age groups were found over time for EASI and IGA; however, differences were rather small (week 52: EASI, 0.3-1.6; IGA, 0.12-0.26). No statistically significant differences between age groups were found for NRS for pruritus. Median thymus- and activation-related chemokine levels considerably decreased from 1751 pg/mL (95% CI, 1614-1900 pg/mL) to 390 pg/mL (95% CI, 368-413 pg/mL) after 6 months of treatment and remained low. Median eosinophil levels temporarily increased up to week 16, with a subsequently statistically significant decrease over time. In total, 306 patients (23.8%) discontinued dupilumab after a median (IQR) of 54.0 (29.0-110.00) weeks, with adverse events among 98 patients (7.6%) and ineffectiveness among 85 patients (6.6%) as the most frequently reported reasons. Forty-one patients (3.2%) restarted dupilumab, and most of these patients recaptured response. Conclusions and Relevance In this cohort study with up to 5 years of follow-up, dupilumab maintained its clinical effectiveness, while two-thirds of patients tapered to a dosing interval of every 3 or 4 weeks. Treatment was discontinued in 23.8% of patients mainly due to adverse events and/or ineffectiveness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- National Expertise Center for Atopic Dermatitis, Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, the Netherlands.
- Department of Dermatology, University Medical Center Groningen, Groningen, the Netherlands.
- Department of Dermatology, Reinier de Graaf Hospital, Delft, the Netherlands.
- Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands.
- Department of Dermatology, Spaarne Gasthuis, Hoofddorp, the Netherlands.
- Department of Dermatology, University Medical Center Maastricht, Maastricht, the Netherlands.
Zitieren
APA
Boesjes, C. M., Kamphuis, E., de Graaf, M., Spekhorst, L. S., Haeck, I., van der Gang, L. F., Loman, L., Zuithoff, N. P. A., Dekkers, C., van der Rijst, L. P., Romeijn, G. L. E., Oosting, A. J., Gostynksi, A., van Lynden-van Nes, A. M. T., Tupker, R. A., van Tuyll van Serooskerken, A. M., Flinterman, A., Politiek, K., Touwslager, W. R. H., …, & de Bruin-Weller, M. S. (2024). Long-Term Effectiveness and Reasons for Discontinuation of Dupilumab in Patients With Atopic Dermatitis. JAMA Dermatology, 160(10), 1044. https://doi.org/10.1001/jamadermatol.2024.2517
Vancouver
Boesjes CM, Kamphuis E, de Graaf M, Spekhorst LS, Haeck I, van der Gang LF, et al. Long-Term Effectiveness and Reasons for Discontinuation of Dupilumab in Patients With Atopic Dermatitis. JAMA Dermatology. 2024;160(10):1044. doi:10.1001/jamadermatol.2024.2517
BibTeX
@article{Boesjes2024,
author = {Boesjes, Celeste M and Kamphuis, Esmé and de Graaf, Marlies and Spekhorst, Lotte S and Haeck, Inge and van der Gang, Lian F and Loman, Laura and Zuithoff, Nicolaas P A and Dekkers, Coco and van der Rijst, Lisa P and Romeijn, Geertruida L E and Oosting, Albert J and Gostynksi, Antoni and van Lynden-van Nes, Anneke M T and Tupker, Ron A and van Tuyll van Serooskerken, Anne-Moon and Flinterman, Annebeth and Politiek, Klaziena and Touwslager, Wouter R H and Christoffers, Wianda A and Stewart, Shiarra M and Kamsteeg, Marijke and Schuttelaar, Marie-Louise A and de Bruin-Weller, Marjolein S},
title = {Long-Term Effectiveness and Reasons for Discontinuation of Dupilumab in Patients With Atopic Dermatitis},
journal = {JAMA Dermatology},
year = {2024},
volume = {160},
number = {10},
pages = {1044},
doi = {10.1001/jamadermatol.2024.2517}
}
EUVIMED